Key Stats for Cytokinetics Stock
- Price change for Cytokinetics stock in last 6 months: 18%
- $CYTK Stock Price as of Aug. 10: $77
- 52-Week High: $88
- $CYTK Stock Price Target: $108
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Cytokinetics (CYTK) stock is extending its rally after Citizens raised its price target to $110 from $105, keeping a Market Outperform rating. The stock has already surged 118% over the past year and now trades around $77.
- The move came after Cytokinetics reported Q2 results that beat expectations across the board.
- Revenue hit $28.6 million, well above the $17.09 million analysts had forecast, driven mainly by early sales of the company’s heart drug MYQORZO.
- The company posted a loss of $1.50 per share, narrower than the $1.64 loss Wall Street expected.
Citizens pointed to the strength of the MYQORZO launch as the main reason for its more bullish price target.
Product sales of roughly $25 million for the quarter came in above both Citizens’ own estimate and the broader consensus. Launches in the U.S. and Europe are both off to a fast start, with management describing launch velocity as exceeding expectations.
According to the company, MYQORZO is doing something notable: it’s both pulling patients away from rival drug CAMZYOS and expanding the overall market for this class of heart medicine.
That combination, taking share while also growing the pie, is generally seen as a strong signal for a new drug’s long-term trajectory.
See analysts’ growth forecasts and price targets for Cytokinetics stock (It’s free) >>>
What the Market Is Telling Us About Cytokinetics Stock
The continued climb in Cytokinetics stock shows investors are rewarding execution on a drug launch that’s still less than six months old.
Beating both revenue and earnings estimates in the same quarter, especially by this wide a margin on revenue, tends to build confidence that a launch has real momentum rather than one-time strength.
Analysts overall maintain a Strong Buy consensus on Cytokinetics stock, with price targets implying 43% upside from current levels.
That said, not everyone views the stock as cheap here. Some valuation models suggest shares may already be priced above fair value given how far the stock has run, and analysts don’t expect the company to turn profitable this year.
That combination, a fast-growing but still unprofitable biopharmaceutical company trading at a premium, is fairly typical for a business in the early innings of a major product launch.
The market’s willingness to keep bidding up Cytokinetics stock despite ongoing losses suggests investors are betting on where MYQORZO sales are headed over the next few years rather than where profitability stands today.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Cytokinetics Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
